Literature DB >> 23100937

PRCA with myelofibrosis: an unusual case report.

Rakhee Kar1, Manoranjan Mahapatra, Hara P Pati.   

Abstract

The association of PRCA and myelofibrosis is very rare with only two such cases reported in the literature. Leukemic transformation in myelofibrosis is known but the progression of PRCA to acute leukemia is very rare. We present an unusual case of PRCA with myelofibrosis which after 14 months of transfusion dependent anemia transformed to acute monocytic leukemia.

Entities:  

Keywords:  Acute Leukemia; Myelofibrosis; PRCA

Year:  2008        PMID： 23100937      PMCID： PMC3453159          DOI： 10.1007/s12288-008-0019-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  10 in total

1.  Pure red cell aplasia evolving through the hyperfibrotic myelodysplastic syndrome to the acute myeloid leukemia: some pathogenetic aspects.

Authors:  N Suvajdzic; D Marisavljevic; V Jovanovic; M Pantic; D Sefer; M Colovic
Journal:  Hematol Cell Ther       Date:  1999-02

Review 2.  T-cell large granular lymphocyte leukemia and related disorders.

Authors:  Michal G Rose; Nancy Berliner
Journal:  Oncologist       Date:  2004

3.  Pure red cell aplasia and myelofibrosis in B-cell neoplasm.

Authors:  Y Hatta; Y Kura; T Yano; H Ushiyama; M Sugitani; T Okano; H Ishizuka; U Sawada; Y Adachi; T Horie
Journal:  J Int Med Res       Date:  2005 Jul-Aug       Impact factor: 1.671

4.  Pure red-cell aplasia in patients with chronic lymphocytic leukemia.

Authors:  G Chikkappa; M H Zarrabi; M F Tsan
Journal:  Medicine (Baltimore)       Date:  1986-09       Impact factor: 1.889

5.  Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.

Authors:  F Cervantes; D Tassies; C Salgado; M Rovira; A Pereira; C Rozman
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

6.  Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.

Authors:  Ruben A Mesa; Chin-Yang Li; Rhett P Ketterling; Georgene S Schroeder; Ryan A Knudson; Ayalew Tefferi
Journal:  Blood       Date:  2004-09-23       Impact factor: 22.113

7.  [Acquired chronic erythroblastopaenia followed by myelofibrosis. Remission with immunosuppressive therapy (author's transl)].

Authors:  F Clément
Journal:  Nouv Presse Med       Date:  1979-11-26

8.  Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis.

Authors:  E Rondeau; P Solal-Celigny; D Dhermy; M Vroclans; N Brousse; J F Bernard; P Boivin
Journal:  Br J Haematol       Date:  1983-03       Impact factor: 6.998

9.  Immunologic abnormalities in myelofibrosis with activation of the complement system.

Authors:  B R Gordon; M Coleman; P Kohen; N K Day
Journal:  Blood       Date:  1981-11       Impact factor: 22.113

10.  Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome.

Authors:  Vinod Pullarkat; Randall D Bass; Jerald Z Gong; Donald I Feinstein; Russell K Brynes
Journal:  Am J Hematol       Date:  2003-01       Impact factor: 10.047
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.